2F5
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
Market Cap & Net Worth: 2F5 (2F5)
2F5 (F:2F5) has a market capitalization of $2.10 Million (€2.05 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #34035 globally and #3883 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2F5's stock price €0.59 by its total outstanding shares 3468225 (3.47 Million).
2F5 Market Cap History: 2026 to 2026
2F5's market capitalization history from 2026 to 2026. Data shows growth from $2.10 Million to $2.10 Million (0.00% CAGR).
2F5 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2F5's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2F5 by Market Capitalization
Companies near 2F5 in the global market cap rankings as of March 19, 2026.
Key companies related to 2F5 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
2F5 Historical Marketcap From 2026 to 2026
Between 2026 and today, 2F5's market cap moved from $2.10 Million to $ 2.10 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of 2F5 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.10 Million USD |
| MoneyControl | $2.10 Million USD |
| MarketWatch | $2.10 Million USD |
| marketcap.company | $2.10 Million USD |
| Reuters | $2.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.